Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated human epidermal growth factor receptor 2 (HER2/neu) positive metastatic breast cancer to assess progression-free survival.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lapatinib (Primary) ; Vinorelbine (Primary)
Indications Advanced breast cancer
Focus Therapeutic Use
Acronyms TyN

Most Recent Events

16 May 2016 Status changed from discontinued to completed.
11 Jun 2015 Status changed from active, no longer recruiting to discontinued as per Australian New Zealand Clinical Trials Registry record.
11 May 2012 Planned number of patients changed from 70 to 20 as reported by Australian New Zealand Clinical Trials Registry.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight